ASCP Corner: Adding Lithium or Anticonvulsants to Antipsychotics for the Treatment of Schizophrenia: Useful Strategy or Exercise in Futility?
J Clin Psychiatry 2009;70(6):932-933
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Clinicians often go to heroic lengths to find effective treatment
strategies for their patients suffering from treatmentresistant
schizophrenia. These approaches include polypharmacy
with other antipsychotics as well as adjunctive medication
strategies with mood stabilizers such as lithium or anticonvulsants.
The hope is for an enhancement of pharmacodynamic
effects so that treatment response is perhaps quicker in onset,
more robust, and enduring.